GM2-gangliosidosis, AB variant

Revision as of 15:24, 9 August 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for GM2-gangliosidosis, AB variant

Articles

Most recent articles on GM2-gangliosidosis, AB variant

Most cited articles on GM2-gangliosidosis, AB variant

Review articles on GM2-gangliosidosis, AB variant

Articles on GM2-gangliosidosis, AB variant in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on GM2-gangliosidosis, AB variant

Images of GM2-gangliosidosis, AB variant

Photos of GM2-gangliosidosis, AB variant

Podcasts & MP3s on GM2-gangliosidosis, AB variant

Videos on GM2-gangliosidosis, AB variant

Evidence Based Medicine

Cochrane Collaboration on GM2-gangliosidosis, AB variant

Bandolier on GM2-gangliosidosis, AB variant

TRIP on GM2-gangliosidosis, AB variant

Clinical Trials

Ongoing Trials on GM2-gangliosidosis, AB variant at Clinical Trials.gov

Trial results on GM2-gangliosidosis, AB variant

Clinical Trials on GM2-gangliosidosis, AB variant at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on GM2-gangliosidosis, AB variant

NICE Guidance on GM2-gangliosidosis, AB variant

NHS PRODIGY Guidance

FDA on GM2-gangliosidosis, AB variant

CDC on GM2-gangliosidosis, AB variant

Books

Books on GM2-gangliosidosis, AB variant

News

GM2-gangliosidosis, AB variant in the news

Be alerted to news on GM2-gangliosidosis, AB variant

News trends on GM2-gangliosidosis, AB variant

Commentary

Blogs on GM2-gangliosidosis, AB variant

Definitions

Definitions of GM2-gangliosidosis, AB variant

Patient Resources / Community

Patient resources on GM2-gangliosidosis, AB variant

Discussion groups on GM2-gangliosidosis, AB variant

Patient Handouts on GM2-gangliosidosis, AB variant

Directions to Hospitals Treating GM2-gangliosidosis, AB variant

Risk calculators and risk factors for GM2-gangliosidosis, AB variant

Healthcare Provider Resources

Symptoms of GM2-gangliosidosis, AB variant

Causes & Risk Factors for GM2-gangliosidosis, AB variant

Diagnostic studies for GM2-gangliosidosis, AB variant

Treatment of GM2-gangliosidosis, AB variant

Continuing Medical Education (CME)

CME Programs on GM2-gangliosidosis, AB variant

International

GM2-gangliosidosis, AB variant en Espanol

GM2-gangliosidosis, AB variant en Francais

Business

GM2-gangliosidosis, AB variant in the Marketplace

Patents on GM2-gangliosidosis, AB variant

Experimental / Informatics

List of terms related to GM2-gangliosidosis, AB variant


GM2-gangliosidosis, AB variant is a rare inherited disorder that causes progressive destruction of nerve cells in the brain and spinal cord. It has a similar pathology to Sandhoff disease and Tay-Sachs disease.

Signs and symptoms of the AB variant begin in infancy. Infants with this disorder typically appear normal until the age of 3 to 6 months, when development slows and muscles used for movement weaken. Affected infants lose motor skills such as turning over, sitting, and crawling. As the disease progresses, infants develop seizures, vision and hearing loss, mental retardation, and paralysis. An eye abnormality called a cherry-red spot, which can be identified with an eye examination, is characteristic of this disorder. Children with the AB variant usually live only into early childhood.

Mutations in the GM2A gene cause GM2-gangliosidosis, AB variant. The GM2A gene provides instructions for making a protein called the GM2 activator. This protein is required for the normal function of beta-hexosaminidase A, a critical enzyme in the nervous system that breaks down a fatty substance called GM2 ganglioside. If mutations disrupt the activity of the GM2 activator, beta-hexosaminidase A cannot perform its normal function. As a result, GM2 ganglioside can accumulate to toxic levels in the brain and spinal cord. Progressive damage caused by the buildup of GM2 ganglioside leads to the destruction of nerve cells, which causes the severe medical problems characteristic of the AB variant. This condition is inherited in an autosomal recessive pattern.

See also

This article incorporates public domain text from The U.S. National Library of Medicine


Template:WikiDoc Sources